QIAGEN powered by

Webinars and events

Loading Events

« All Events

  • This event has passed.

What’s new in QIAGEN CLC Genomics Workbench version 24 – EMEA/APAC

January 30, 2024 @ 10:00 am - 11:00 am

QIAGEN CLC Genomics Workbench version 24 is here with exciting updates we’d like to share with you. These include:

  • Our QIAGEN CLC LightSpeed Module which now provides ultrafast somatic workflows
  • Spatial Transcriptomics and ParseBio support in QIAGEN CLC Single Cell Analysis Module
  • Amplicon classification for ONT reads in QIAGEN CLC Microbial Genomics Module
  • New Structural variant detection for long read and De novo assembly of PacBio HiFi reads
  • Importer for Element, PacBio Onso, Ultima reads, Singular
  • CRAM format importer / exporter
  • Fancy new interactive RNAseq Volcano plot for RNAseq
  • And many more new and improved workflow and reporting capabilities

Join this webinar to:

  • Learn how to take advantage of the latest improvements
  • Get an overview of the many tools available to you
  • Make sure to join this webinar to elevate your understanding of current trends in bioinformatics

Can’t make it at this time? Don’t worry. Register now and we will send you the on-demand recording so you can catch up on what you missed.

On-demand Webinars


  • Comprehensive Molecular Tumor Analysis (CMTA) integrating RNAseq and tumor immune microenvironment (TME) for targeted therapy

    Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However, deeper molecular insights are needed to improve personalized treatment decisions that are tailored to specific molecular characteristics of a tumor. Integrating gene expression analysis in personalized oncology provides an add...

  • Mining curated knowledge graphs and validating with experimental datasets to accelerate your drug target discovery

    In an era of near-limitless public experimental data but little standardization, meaningful insights are lost to noise. Large collections of quality experimental data are essential for big-picture discoveries that stand up to scrutiny.  In this webinar, you will learn how to feed your drug discovery programs by integrating connections mined from QIAGEN Biomedical Kn...

  • Translating COSMIC's gold standard data into actionable insights

    As the vast landscape of genetic oncology continues to expand, the ability to understand and utilize the full potential of this rich data becomes increasingly challenging. As a result, researchers, scientists, and clinicians need an accessible, streamlined and standardized way of keeping track of this potentially crucial, ever-growing body of actionable knowledge. Ove...

  • Target exploration and cell line selection for drug discovery

    Cancer cell line models have been a cornerstone of cancer research for decades. Cancer cell lines profiling can be a powerful tool for the identification of genes’ alterations or pathways cancer-related and for the discovery of putative drug targets. This webinar will focus using Qiagen OmicSoft Lands and Ingenuity Pathway Analysis as guides for the selection of cel...

  • How to perform DNA-seq and resequencing data analyses using QIAGEN CLC Genomics Workbench

    In this webinar, we’ll introduce algorithms required to perform data analysis for resequencing next-generation sequencing data. Together, we’ll explore:  • Read mapper • Variant callers • Annotations and filters • Genome Browser  Bring any questions you may have, and we will answer them during the webinar. ...

  • One tool to help biopharma accelerate cancer drug discovery and repurposing: A translational research use-case and discussion

    The development of new cancer drugs is challenging, costly, and time-consuming. As translational research on cancer diagnostics and genomic profiling rapidly evolves, the ability to confidently and efficiently identify specific oncogenes and tumor suppressors involved in oncogenesis is becoming increasingly difficult. This brief half-hour webinar is intended for bi...